Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Effect of dipyridamole plus aspirin on hemodialysis graft patency.

Dixon BS, Beck GJ, Vazquez MA, Greenberg A, Delmez JA, Allon M, Dember LM, Himmelfarb J, Gassman JJ, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Fenves AZ, Kaufman JS, Cotton JR Jr, Martin KJ, McNeil JW, Rahman A, Lawson JH, Whiting JF, Hu B, Meyers CM, Kusek JW, Feldman HI; DAC Study Group.

N Engl J Med. 2009 May 21;360(21):2191-201. doi: 10.1056/NEJMoa0805840.

2.

Use of aspirin associates with longer primary patency of hemodialysis grafts.

Dixon BS, Beck GJ, Dember LM, Vazquez MA, Greenberg A, Delmez JA, Allon M, Himmelfarb J, Hu B, Greene T, Radeva MK, Davidson IJ, Ikizler TA, Braden GL, Lawson JH, Cotton JR Jr, Kusek JW, Feldman HI; Dialysis Access Consortium (DAC) Study Group.

J Am Soc Nephrol. 2011 Apr;22(4):773-81. doi: 10.1681/ASN.2010060582. Epub 2011 Mar 17.

3.

Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.

Bedenis R, Lethaby A, Maxwell H, Acosta S, Prins MH.

Cochrane Database Syst Rev. 2015 Feb 19;(2):CD000535. doi: 10.1002/14651858.CD000535.pub3. Review.

PMID:
25695213
4.

Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.

Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group.

Clin Trials. 2005;2(5):400-12.

PMID:
16317809
5.

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW; PRoFESS Study Group.

N Engl J Med. 2008 Sep 18;359(12):1238-51. doi: 10.1056/NEJMoa0805002. Epub 2008 Aug 27.

6.

Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial.

McCollum C, Alexander C, Kenchington G, Franks PJ, Greenhalgh R.

J Vasc Surg. 1991 Jan;13(1):150-61; discussion 161-2.

PMID:
1987387
8.

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.

Tanner NC, Da Silva A.

Cochrane Database Syst Rev. 2015 Jul 16;(7):CD002786. doi: 10.1002/14651858.CD002786.pub3. Review.

PMID:
26184395
9.

Dipyridamole plus aspirin and hemodialysis graft patency.

Hentschel DM.

N Engl J Med. 2009 Aug 13;361(7):720-1; author reply 721. No abstract available.

PMID:
19681176
10.

Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting.

Rajah SM, Nair U, Rees M, Saunders N, Walker D, Williams G, Critchley A, Beton D, Campbell C, Lawson RA, et al.

J Thorac Cardiovasc Surg. 1994 Apr;107(4):1146-53.

PMID:
8159037
11.

Dipyridamole plus aspirin and hemodialysis graft patency.

Weale AR, Cooper DG.

N Engl J Med. 2009 Aug 13;361(7):720; author reply 721. doi: 10.1056/NEJMc091312. No abstract available.

PMID:
19675337
12.

Antiplatelet therapy and vascular-access patency.

Lok CE.

N Engl J Med. 2009 May 21;360(21):2240-2. doi: 10.1056/NEJMe0902841. No abstract available.

PMID:
19458370
13.

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.

Belch JJ, Dormandy J; CASPAR Writing Committee, Biasi GM, Cairols M, Diehm C, Eikelboom B, Golledge J, Jawien A, Lepäntalo M, Norgren L, Hiatt WR, Becquemin JP, Bergqvist D, Clement D, Baumgartner I, Minar E, Stonebridge P, Vermassen F, Matyas L, Leizorovicz A.

J Vasc Surg. 2010 Oct;52(4):825-33, 833.e1-2. doi: 10.1016/j.jvs.2010.04.027. Epub 2010 Aug 1. Erratum in: J Vasc Surg. 2011 Feb;53(2):564. Biasi, B M [corrected to Biasi, G M].

14.

Cost-effectiveness of antiplatelet therapy to prolong primary patency of hemodialysis graft.

Nee R, Parker AL, Little DJ, Yuan CM, Himmelfarb J, Lowe SR, Abbott KC.

Clin Nephrol. 2014 Jan;81(1):38-51. doi: 10.5414/CN108100.

PMID:
24161074
15.

Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study.

Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM.

Kidney Int. 1994 May;45(5):1477-83.

16.
17.

Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands.

van der Meer J, Hillege HL, Kootstra GJ, Ascoop CA, Mulder BJ, Pfisterer M, van Gilst WH, Lie KI.

Lancet. 1993 Jul 31;342(8866):257-64. Erratum in: Lancet 1993 Sep 11;342(8872):690.

PMID:
8101300
19.

Effect of low dose aspirin and dipyridamole on primary patency of arteriovenous grafts in hemodialysis patients: a randomized double-blind placebo-controlled trial.

Tayebi P, Kazemzadeh G, Banihashem A, Ravari H.

Electron Physician. 2018 Jan 25;10(1):6135-6139. doi: 10.19082/6135. eCollection 2018 Jan.

20.

Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis grafts: a randomized controlled trial.

Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Dorval M, Oliver M, Donnelly S, Allon M, Stanley K; Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study Group.

JAMA. 2012 May 2;307(17):1809-16. doi: 10.1001/jama.2012.3473.

Supplemental Content

Support Center